2X1 Stock Chart & Stats
€97.80
-€1.70(-1.49%)
At close: 4:00 PM EDT
€97.80
-€1.70(-1.49%)
Day’s Range― - ―
52-Week Range€60.85 - €137.40
Previous CloseN/A
Volume455.00
Average Volume (3M)1.69K
Market Cap
€7.11B
Enterprise Value€8.80K
Total Cash (Recent Filing)€410.68M
Total Debt (Recent Filing)€1.21M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Dec 14, 2026EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.71
Shares Outstanding87,350,044
10 Day Avg. Volume2,206
30 Day Avg. Volume1,690
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)18.39
Price to Sales (P/S)0.00
P/FCF Ratio-51.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€132.00Price Target Upside34.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.29
Revenue Forecast (FY)€3.80M
Bulls Say, Bears Say
Bulls Say
Focused Clinical Platform With Expansion PotentialObefazimod gives Abivax a focused development platform in chronic inflammatory disease, while oral dosing and potential use beyond ulcerative colitis could broaden the opportunity. If development succeeds, this may support expansion across indications without requiring an entirely separate technology.
Improved Balance Sheet And Low LeverageThe materially stronger 2025 balance sheet provides greater financial flexibility than in prior periods. Low debt relative to equity can reduce near-term solvency pressure and leave more capacity to fund clinical development, although it does not eliminate the need for future financing.
Strong Historical Gross-margin ProfileNear-100% historical gross margins suggest the underlying product economics can be attractive when revenue is generated. That profile could provide meaningful operating leverage after commercialization, though the benefit remains unproven at scale because recent revenue has been absent.
Bears Say
Dependence On External FinancingWithout recurring product sales, Abivax must rely on equity raises or potential licensing and collaboration proceeds to fund research and operations. This dependence can dilute shareholders, constrain strategic flexibility, and make long-term execution sensitive to access to capital.
Persistent And Significant Cash BurnContinued negative operating and free cash flow means the business is not self-funding its clinical programs. Sustained annual cash burn will require ongoing financing or other cash inflows, increasing funding risk and potentially limiting the pace or scope of development if capital becomes less available.
Deepening Losses And Unstable RevenueThe combination of widening losses and zero reported revenue shows that current financial performance remains driven by development spending rather than commercial traction. Until revenue becomes recurring, earnings visibility will remain weak and the company’s path to profitability will depend on successful clinical and regulatory progress.
Abivax SA News
2X1 FAQ
What was Abivax SA’s price range in the past 12 months?
Abivax SA lowest stock price was €60.85 and its highest was €137.40 in the past 12 months.
What is Abivax SA’s market cap?
Abivax SA’s market cap is €7.11B.
When is Abivax SA’s upcoming earnings report date?
Abivax SA’s upcoming earnings report date is Dec 14, 2026 which is in 78 days.
How were Abivax SA’s earnings last quarter?
Abivax SA released its earnings results on Sep 21, 2026. The company reported -€1.47 earnings per share for the quarter, missing the consensus estimate of -€0.801 by -€0.669.
Is Abivax SA overvalued?
According to Wall Street analysts Abivax SA’s price is currently Undervalued.
Does Abivax SA pay dividends?
Abivax SA does not currently pay dividends.
What is Abivax SA’s EPS estimate?
Abivax SA’s EPS estimate is -0.87.
How many shares outstanding does Abivax SA have?
Abivax SA has 87,350,044 shares outstanding.
What happened to Abivax SA’s price movement after its last earnings report?
Abivax SA reported an EPS of -€1.47 in its last earnings report, missing expectations of -€0.801. Following the earnings report the stock price went down -4.643%.
Which hedge fund is a major shareholder of Abivax SA?
Currently, no hedge funds are holding shares in DE:2X1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abivax SA
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
2X1 Stock 12 Month Forecast
Average Price Target
€132.00
▲(34.97% Upside)